Enzychem Lifesciences Corporation

As of June 30, 2026, Enzychem Lifesciences Corporation has 84.64M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.15, and the price-to-book ratio stands at 0.58.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2026, Enzychem Lifesciences Corporation maintains a current ratio of 13.12, meaning it holds 13.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.92, indicating elevated leverage, while an interest coverage ratio of -70.83 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Enzychem Lifesciences Corporation posted a negative return on equity (ROE) of -12.04, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.59, reflecting losses generated across the asset base. Inventory turnover of 4.03 indicates how many times Enzychem Lifesciences Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on April 22, 2026, Enzychem Lifesciences Corporation's stock has declined approximately 18.25% over the past 52 weeks. The 50-day moving average sits at 1,060.76, while the 200-day moving average is 1,132.29.

Over the twelve months ended June 30, 2026, Enzychem Lifesciences Corporation posted a gross margin of 4.90, reflecting its pricing power and cost economics. The operating margin of -20.78 and net profit margin of -26.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -23.53: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.28, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Enzychem Lifesciences Corporation shareholders.

Enzychem Lifesciences Corporation's most recent stock split took place on August 17, 2022 with a 1:6 split ratio.

As of June 30, 2026, Enzychem Lifesciences Corporation has an Altman Z-Score of 3.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.